Q1 Earnings Forecast for BDTX Issued By Wedbush

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) - Equities researchers at Wedbush issued their Q1 2026 EPS estimates for shares of Black Diamond Therapeutics in a note issued to investors on Friday, March 7th. Wedbush analyst R. Driscoll forecasts that the company will earn ($0.22) per share for the quarter. Wedbush currently has a "Outperform" rating and a $11.00 target price on the stock. The consensus estimate for Black Diamond Therapeutics' current full-year earnings is ($1.30) per share. Wedbush also issued estimates for Black Diamond Therapeutics' Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.23) EPS and Q4 2026 earnings at ($0.24) EPS.

Separately, Stifel Nicolaus dropped their price target on shares of Black Diamond Therapeutics from $16.00 to $15.00 and set a "buy" rating on the stock in a research note on Friday, March 7th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $14.40.

Black Diamond Therapeutics Trading Down 6.9 %

Black Diamond Therapeutics stock traded down $0.12 during mid-day trading on Monday, hitting $1.67. The company had a trading volume of 180,076 shares, compared to its average volume of 814,045. Black Diamond Therapeutics has a 12 month low of $1.59 and a 12 month high of $7.66. The stock's 50 day moving average price is $2.21 and its two-hundred day moving average price is $3.09. The company has a market capitalization of $94.33 million, a PE ratio of -1.25 and a beta of 2.52.

Remove Ads

Black Diamond Therapeutics (NASDAQ:BDTX - Get Free Report) last issued its quarterly earnings results on Thursday, March 6th. The company reported ($0.28) EPS for the quarter, topping analysts' consensus estimates of ($0.31) by $0.03.

Institutional Investors Weigh In On Black Diamond Therapeutics

Large investors have recently bought and sold shares of the business. Intech Investment Management LLC bought a new position in Black Diamond Therapeutics during the 3rd quarter valued at about $56,000. Charles Schwab Investment Management Inc. lifted its position in Black Diamond Therapeutics by 6.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 109,224 shares of the company's stock valued at $475,000 after purchasing an additional 7,021 shares during the period. FMR LLC purchased a new stake in Black Diamond Therapeutics in the third quarter worth approximately $779,000. MetLife Investment Management LLC grew its position in Black Diamond Therapeutics by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 22,286 shares of the company's stock worth $97,000 after purchasing an additional 12,557 shares during the period. Finally, Walleye Capital LLC purchased a new stake in Black Diamond Therapeutics during the 3rd quarter valued at $49,000. 95.47% of the stock is currently owned by institutional investors.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.